Recent news coverage reflects mixed market reactions to VASO Corp's quarterly earnings, highlighting revenue growth alongside margin and profit fluctuations.

• VASO stock declined following Q4 earnings despite revenue growth, indicating market concerns about profitability or margins [N1].
• The company experienced a profit turnaround and strong Q3 earnings, which positively influenced stock performance [N4].
• Stock price fell after Q2 earnings due to declines in revenue and margins [N7].
• Stock slipped post Q1 earnings despite record revenue growth, suggesting investor focus on profitability metrics [N8].
• Multiple analyst blogs and reports have highlighted VASO alongside other healthcare and technology companies, indicating ongoing analyst interest [N2][N5].

VASO Corp's diversified business model across IT services, professional sales, and proprietary medical equipment provides multiple avenues for revenue generation. The exclusive sales agreement with GE HealthCare Technologies offers a stable channel for medical equipment sales in the U.S. The company's proprietary cardiovascular devices and cloud-based software solutions position it well in specialized healthcare markets. Recent revenue growth in the professional sales segment and the company's liquidity position support operational stability. Strategic divestitures, such as the sale of its healthcare IT business, indicate active portfolio management to focus on core strengths.

VASO Corp faces significant risks from its heavy reliance on the GE HealthCare sales agreement, which accounts for approximately 50% of revenue and all operating income. Termination or non-renewal of this agreement could materially impact financial performance. The company also contends with supply chain challenges affecting equipment delivery, regulatory compliance risks in multiple jurisdictions, and operational risks related to its foreign business, particularly in China. Profitability has shown variability, with adjusted EBITDA turning negative in 2025. Competitive pressures in both medical equipment and IT services segments may constrain growth and margins.

VASO Corp's moat is supported by its exclusive sales representation agreement with GE HealthCare Technologies, which provides access to a significant portion of the U.S. healthcare equipment market. The company's proprietary cardiovascular medical devices and software, including EECP therapy systems and cloud-based diagnostic tools, benefit from in-house intellectual property and engineering capabilities. Its established sales force and proprietary sales management tools enhance market penetration. Additionally, the company's diversified operations across IT services, professional sales, and equipment manufacturing provide multiple revenue streams. However, the reliance on the GE HealthCare agreement and competitive pressures in medical equipment and IT services present challenges to sustaining a strong moat.

• Dependence on GE HealthCare Agreement: Approximately 50% of revenue and all operating income derive from the exclusive sales representation agreement with GE HealthCare Technologies, which expires in 2030 but may be terminated earlier. Loss or non-renewal of this agreement would materially affect financial results.
• Supply Chain and Delivery Risks: Delays or interruptions in equipment production and delivery, especially due to supply chain issues like chip shortages, could negatively impact sales and customer satisfaction.
• Regulatory Compliance: The company operates in heavily regulated medical device markets requiring FDA and other approvals. Non-compliance or regulatory changes could disrupt operations.
• Foreign Operations Risks: Operations in China expose the company to currency, legal, political, and tax risks, as well as uncertainties in commercial law and regulatory environments.
• Profitability and Margin Pressure: Adjusted EBITDA declined to a negative figure in 2025, indicating margin pressures and operational challenges that could affect financial stability.

• VASO Corp operates in three main segments: IT (through VasoTechnology, Inc.), Professional Sales Service (through VasoHealthcare), and Equipment (through VasoMedical, Inc.).
• The IT segment focuses on managed network infrastructure, transport, and security services; healthcare IT services were divested in November 2025.
• The Professional Sales Service segment is the exclusive sales representative for GE HealthCare Technologies (GEHC) diagnostic imaging and ultrasound equipment in specific U.S. market segments, with a team of over 90 sales professionals.
• The Equipment segment designs, manufactures, sells, and services proprietary cardiovascular medical devices and software, including EECP therapy systems, Biox Holter monitors, ARCS cloud-based ECG and blood pressure analysis software (SaaS), and MobiCare wireless vital-sign monitoring.
• The Equipment segment sells directly in the U.S. and China and through distributors internationally.
• The company holds a 49% minority interest in EECP Global Corporation, which it manages domestically under a management service agreement.
• The GEHC sales representation agreement extends through December 31, 2030, subject to earlier termination conditions.
• For the fiscal year ended December 31, 2025, total revenue was $89.1 million, with net income of $1.57 million and basic and diluted EPS of $0.01 per share.
• Revenue by segment in 2025: IT segment approximately $42.5 million (slight decrease from prior year), Professional Sales Service segment $44.2 million (6.9% increase), Equipment segment $2.44 million (1.5% decrease).
• The company recorded gross profit of $54.7 million in 2025.
• Liquidity as of December 31, 2025: cash and cash equivalents $35.05 million, current assets $58.56 million, current liabilities $36.85 million, current ratio 1.59, cash ratio 1.07.
• The company sold its healthcare IT business unit (VasoHealthcare IT) to Nano-X Imaging Ltd in November 2025.
• The company has a revolving credit agreement of $3 million renewed through July 31, 2026, with no amounts drawn as of December 31, 2025.
• The company faces competition in its segments from major medical equipment manufacturers and IT service providers.
• Risks include reliance on the GEHC agreement for approximately 50% of revenue and all operating income, potential termination or non-renewal of this agreement, supply chain issues affecting GEHC equipment delivery, regulatory compliance risks, and risks related to foreign operations, especially in China.
• The company has a history dating back to 1987, originally focused on EECP therapy systems, and has diversified since 2010.
• Recent news indicates mixed stock performance following quarterly earnings, with revenue growth but some margin pressures and profit fluctuations reported.
• The company terminated a business combination agreement with Achari Ventures Holdings Corp in 2024.
• The company uses proprietary sales management and analytic tools to increase market penetration in the Professional Sales Service segment.